VYNE Therapeutics Inc - VYNE Enterprise Value-to-Revenue Multiple

Public company logo of VYNE Therapeutics, Inc. (VYNE)

The GURU.Markets platform displays a chart of the enterprise value-to-revenue ratio, where the -844.44 mark serves as the current metric for the InhiX precision immunodermatology system. VYNE Therapeutics (VYNE) is implementing advanced inflammation therapy methods in collaboration with clinical centers. Production stability is ensured by the precise calibration of filling lines at partner plants, which supports the business's operational efficiency.

VYNE Therapeutics Inc - VYNE Company Value to Revenue (period 11/23/2025 - 07/28/2026)

VYNE Therapeutics Inc - analytical breakdowns and key metrics (VYNE)

- share price and consensus valuation forecast:
- money and cash flow information:
Initial company analysis:VYNE Therapeutics, Inc. VYNE
Product sample of VYNE Therapeutics, Inc.

This ratio compares the total enterprise value, including net debt, to the volume of generated sales, allowing for an assessment of the asset's market value regardless of its financing structure. By analyzing the enterprise value-to-revenue multiple, an investor can differentiate fundamental overheating from a premium attributed to the highly specialized BET inhibitor pipeline of VYNE (VYNE), which is currently in the active phase of clinical trials.